Industry News
Share your love

Zeiss Completes Acquisition of DORC
In a significant move for the ophthalmology sector, Carl Zeiss Meditec announced the successful acquisition of 100% shares of the Dutch Ophthalmic Research Center (DORC), a transaction that has now received all necessary regulatory approvals. This acquisition from Eurazeo SE,…

Qlaris Bio Begins Phase 2 Trials of QLS-111 for Eye Conditions
Qlaris Bio has commenced two critical Phase 2 trials in the United States for its innovative intraocular pressure (IOP)-lowering product, QLS‑111. These masked, randomized clinical trials are designed to investigate the efficacy of QLS‑111 in patients suffering from ocular hypertension…

West Point and Verséa Sign Supply Deal for Ocular Products
In a significant move for ocular health and treatment, West Point Optical Group (WPOG), the operator of 86 Pearle Vision stores, has joined forces with Verséa Ophthalmics in an exclusive partnership supply agreement. Under this new deal, Verséa Ophthalmics is…

Melt Pharma Raises $24M for Sedation Tablet
Melt Pharmaceuticals has successfully completed a significant financial milestone, securing approximately $24 million through its Series B Preferred Stock financing round. This latest funding round saw contributions from both new and returning investors, setting the stage for the accelerated development…

Pantheon Vision Gets Another $1.8M for Corneal Implants
Pantheon Vision, a pioneering medical device company in the pre-clinical stage focused on developing bioengineered corneal implants, has secured an additional $1.8 million in funding. This recent financial boost is part of a second tranche from KeraLink International (KLI), following…

CSI Dry Eye Software Unveils Version 5.0 Update
CSI Dry Eye Software, a leading innovator in the field of artificial intelligence for eye care, has officially announced the release of its latest software update, Version 5.0. This update marks a significant leap forward in the company’s mission to…

Viatris Launches RYZUMVI™ 0.75% in the United States
Viatris Inc. announced the commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) 0.75% in the United States. This treatment is the only FDA-approved eye drop available in the U.S. market designed to reverse pharmacologically-induced mydriasis, commonly caused by adrenergic agonists like…
Alcon Names Terry Kim, MD as Chief Medical Officer
Alcon announced the appointment of Terry Kim, MD, as the company’s new Chief Medical Officer (CMO) and Head of Global Medical Safety, starting in April. Dr. Kim, a renowned figure in the field of ophthalmology, brings a wealth of experience…

Aldeyra Eyes NDA Resubmission for DED Treatment
Aldeyra Therapeutics announced its clinical development strategy aimed at the resubmission of a New Drug Application (NDA) for its topical ocular 0.25% reproxalap. This investigational RASP modulator is poised for the treatment of dry eye disease, pending approval from the…

ASCRS Congress 2024 Set to Take Place in April 5-8
From April 5 to 8, 2024, the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting is set to take place in Boston, USA, at the Boston Convention & Exhibition Center. This annual meeting is a pivotal event for…



